Food allergies are treated through a combination of strict allergen avoidance, emergency preparedness for accidental exposures, and in some cases, therapies that gradually raise your tolerance to a trigger food. The right approach depends on the type and severity of your allergy, your age, and how many foods are involved. Treatment has changed significantly in recent years, with new FDA-approved options that go beyond simply avoiding problem foods.
Allergen Avoidance: The Foundation
For most people with food allergies, daily management still centers on avoiding trigger foods entirely. U.S. food labeling law requires manufacturers to clearly identify nine major allergens on packaged foods: milk, eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans, and sesame. Sesame was added to the list most recently, becoming the ninth required allergen on labels starting January 1, 2023.
Reading labels becomes a habit, but it’s not foolproof. Allergens can hide under unfamiliar ingredient names, and cross-contact during manufacturing or restaurant preparation is always a risk. That’s why avoidance is paired with having a plan for when things go wrong.
Emergency Treatment for Severe Reactions
Epinephrine is the first-line treatment for anaphylaxis, the most dangerous type of allergic reaction. It works by rapidly opening airways, raising blood pressure, and reducing swelling. Auto-injectors deliver a pre-measured dose into the outer thigh. Adults and children weighing 30 kg (about 66 pounds) or more receive a 0.3 mg dose. Smaller children get lower doses based on weight: 0.15 mg for those between 15 and 30 kg, and 0.1 mg for children between 7.5 and 15 kg. The injection can be repeated every 5 to 10 minutes if symptoms don’t improve.
Carrying two auto-injectors at all times is standard practice, since a single dose doesn’t always resolve a reaction. An emergency action plan, ideally written with your allergist, spells out exactly what symptoms to watch for and when to inject. For children, this plan should be shared with schools, caregivers, and anyone who regularly supervises meals. Teachers and school nurses need to be trained to recognize anaphylaxis and use the auto-injector themselves, because speed matters.
Oral Immunotherapy
Oral immunotherapy, or OIT, works by feeding you tiny, gradually increasing amounts of your allergen over months, training your immune system to tolerate it. The goal isn’t to let you eat the food freely. It’s to raise the threshold at which you react, so an accidental bite of something at a party doesn’t send you to the emergency room.
The process has three phases. During the first visit, you receive very small doses under medical supervision to find your starting point. Then comes a build-up phase where you eat a small daily dose at home, returning to the clinic every few weeks to increase the amount. This phase typically takes around four months at minimum. Once you reach a target maintenance dose, you stay on that daily dose long-term to keep your tolerance.
Palforzia is the only FDA-approved oral immunotherapy product, designed specifically for peanut allergy in patients ages 4 through 17 (though use can continue into adulthood). Its maintenance dose is 300 mg of peanut protein daily, roughly equivalent to one peanut. In clinical research on peanut OIT more broadly, build-up phases have reached maintenance doses as high as 795 mg of peanut protein. Side effects are common, mostly mild: itchy mouth, stomach discomfort, and nausea. Some people drop out because of persistent gastrointestinal symptoms.
For milk allergy, studies show that 67 to 92 percent of people completing OIT were able to include milk in their diet by the end of treatment, compared to none in placebo groups. These are promising numbers, though the trade-off is a higher risk of allergic side effects during treatment compared to other approaches.
Sublingual Immunotherapy
Sublingual immunotherapy takes a similar concept but uses much smaller doses. A liquid containing the food protein is held under the tongue for two minutes, then swallowed. The doses are far lower than OIT because they’re limited by how much liquid fits under your tongue and how concentrated the extract can be made.
The trade-off is straightforward: sublingual therapy causes fewer and milder side effects, but it also produces less desensitization. In peanut studies, sublingual immunotherapy allowed 52 to 100 percent of participants to pass food challenges after treatment, depending on the study and dose used. It’s not yet FDA-approved for food allergy but is actively studied, particularly for younger children where the gentler safety profile is appealing.
The Peanut Patch
Epicutaneous immunotherapy delivers allergen through a small patch worn on the skin. A phase 3 trial published in the New England Journal of Medicine tested a patch containing 250 micrograms of peanut protein in toddlers ages 1 to 3. After 12 months, 67 percent of children wearing the peanut patch could tolerate significantly more peanut protein without reacting, compared to 33.5 percent in the placebo group.
This approach is especially significant because no approved desensitization therapies currently exist for children under 4. The patch is not yet FDA-approved but is under regulatory review. Its appeal lies in its simplicity: no daily oral doses, no holding liquid under a toddler’s tongue. You apply it and go about your day.
Xolair for Multiple Food Allergies
In February 2024, the FDA approved Xolair (omalizumab) as the first medication to reduce allergic reactions to more than one food at a time. This is a significant shift. Until this approval, every desensitization therapy targeted a single allergen, which left people allergic to multiple foods with limited options.
Xolair is an injectable medication given every two to four weeks. It works by binding to the antibodies (IgE) that trigger allergic reactions, blocking them before they can set off symptoms. In the pivotal trial of 168 people allergic to peanut plus at least two other foods, 68 percent of those receiving Xolair could consume a dose of peanut protein without moderate to severe symptoms after 16 to 20 weeks, compared to just 6 percent on placebo. Results were similarly strong for other allergens: 67 percent tolerated egg protein (versus 0 percent on placebo), 66 percent tolerated milk (versus 11 percent), and 42 percent tolerated cashew (versus 3 percent).
Xolair doesn’t cure food allergies or replace avoidance. It raises the amount of allergen your body can handle before reacting, providing a safety net against accidental exposures. It’s approved for adults and children 1 year and older with IgE-mediated food allergy.
Treatment for Non-IgE Food Allergies
Not all food allergies involve the classic IgE pathway that causes hives, throat swelling, or anaphylaxis. Food Protein-Induced Enterocolitis Syndrome (FPIES) is a non-IgE reaction that primarily affects infants and young children, causing severe vomiting and diarrhea hours after eating a trigger food. The most common triggers are cow’s milk, oat, rice, avocado, egg, and peanut. Banana, apple, and sweet potato are also frequent culprits.
FPIES doesn’t respond to epinephrine or antihistamines because the immune mechanism is different. Management relies on identifying and strictly avoiding trigger foods, then periodically re-testing tolerance through supervised food challenges, typically every 12 to 18 months. During acute reactions, the priority is preventing dehydration. An anti-nausea medication can be given at home for children over 6 months. About 15 percent of children experiencing a severe FPIES reaction develop enough fluid loss to cause a dangerous drop in blood pressure, requiring emergency IV fluids. Most children outgrow FPIES, but the timeline varies by trigger food.
Choosing the Right Approach
Your treatment path depends on several factors. If you have a single food allergy, particularly peanut, oral immunotherapy or the peanut patch (once available for your age group) may be an option. If you’re allergic to multiple foods, Xolair offers something no other therapy currently can. If your child is very young, patch therapy may eventually fill a gap that other treatments don’t cover yet.
All of these therapies share a common reality: they reduce reactivity but don’t eliminate allergy. You still need to avoid your trigger foods intentionally. The difference is that if a restaurant makes a mistake or a label is unclear, your body has more room to handle the exposure without a dangerous reaction. Carrying epinephrine remains essential regardless of which treatment you’re on.